Journal article icon

Journal article

The treatment of patients with low tumour burden and/or slow growing disease.

Abstract:

In the evaluation of the wide range of novel therapeutics which have been developed, investigators do not have to be tied to the current paradigm of demonstrating additive efficacy to first line combination therapy. The addition of new agents to FOLFOX regimens has proved a high hurdle at which many promising agents have fallen. In those patients with slow growing disease or low tumour burden both the use of novel agents in a window of opportunity trial before conventional chemotherapy or in ...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Journal:
European journal of cancer (Oxford, England : 1990)
Volume:
47 Suppl 3
Issue:
SUPPL. 3
Pages:
S67-S75
Publication date:
2011-09-05
DOI:
EISSN:
1879-0852
ISSN:
0959-8049
URN:
uuid:aa1323d8-cad5-412e-a351-cbd4d0a3ecaa
Source identifiers:
186126
Local pid:
pubs:186126

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP